Literature DB >> 10860949

Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system.

R P Phipps1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10860949      PMCID： PMC34362          DOI： 10.1073/pnas.97.13.6930

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  20 in total

Review 1.  CD40 and its ligand in host defense.

Authors:  R J Noelle
Journal:  Immunity       Date:  1996-05       Impact factor: 31.745

Review 2.  CD40-mediated signaling in B cells. Balancing cell survival, growth, and death.

Authors:  M R Kehry
Journal:  J Immunol       Date:  1996-04-01       Impact factor: 5.422

Review 3.  CD40-CD40 ligand.

Authors:  C van Kooten; J Banchereau
Journal:  J Leukoc Biol       Date:  2000-01       Impact factor: 4.962

4.  Requirement for CD154 in the progression of atherosclerosis.

Authors:  E Lutgens; L Gorelik; M J Daemen; E D de Muinck; I S Grewal; V E Koteliansky; R A Flavell
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

5.  CD40 expression by human fibroblasts.

Authors:  K M Fries; G D Sempowski; A A Gaspari; T Blieden; R J Looney; R P Phipps
Journal:  Clin Immunol Immunopathol       Date:  1995-10

6.  Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes.

Authors:  P Aukrust; F Müller; T Ueland; T Berget; E Aaser; A Brunsvig; N O Solum; K Forfang; S S Frøland; L Gullestad
Journal:  Circulation       Date:  1999-08-10       Impact factor: 29.690

7.  Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype.

Authors:  E Lutgens; K B Cleutjens; S Heeneman; V E Koteliansky; L C Burkly; M J Daemen
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

8.  Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice.

Authors:  U Schönbeck; G K Sukhova; K Shimizu; F Mach; P Libby
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

9.  Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions.

Authors:  U Schönbeck; G K Sukhova; P Graber; S Coulter; P Libby
Journal:  Am J Pathol       Date:  1999-10       Impact factor: 4.307

10.  Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40.

Authors:  F H Durie; R A Fava; T M Foy; A Aruffo; J A Ledbetter; R J Noelle
Journal:  Science       Date:  1993-09-03       Impact factor: 47.728
View more
  42 in total

1.  Platelet microparticles and platelet adhesion: therapeutic implications for the prevention and treatment of stroke.

Authors:  Kiat T Tan; Gregory Y H Lip
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-05

Review 2.  Inflammation and atherosclerosis.

Authors:  Mehdi H Shishehbor; Deepak L Bhatt
Journal:  Curr Atheroscler Rep       Date:  2004-03       Impact factor: 5.113

3.  Pathogen-mediated inflammatory atherosclerosis is mediated in part via Toll-like receptor 2-induced inflammatory responses.

Authors:  Chie Hayashi; Andres G Madrigal; Xinyan Liu; Takashi Ukai; Sulip Goswami; Cynthia V Gudino; Frank C Gibson; Caroline A Genco
Journal:  J Innate Immun       Date:  2010-05-10       Impact factor: 7.349

4.  Soluble CD40 ligand levels in acute pulmonary embolism: a prospective, randomized, controlled study.

Authors:  Zeynettin Kaya; Kurtulus Ozdemir; Mehmet Kayrak; Enes Elvin Gul; Gokhan Altunbas; Cetin Duman; Aysel Kiyici
Journal:  Heart Vessels       Date:  2011-04-14       Impact factor: 2.037

5.  Developmental changes in soluble CD40 ligand.

Authors:  Jill M Cholette; Neil Blumberg; Richard P Phipps; Michael P McDermott; Kelly F Gettings; Norma B Lerner
Journal:  J Pediatr       Date:  2007-10-24       Impact factor: 4.406

6.  Frontline Science: c-Myc regulates P-selectin glycoprotein ligand-1 expression in monocytes during HIV-1 infection.

Authors:  Ryan Connor; Letitia D Jones; Xing Qiu; Juilee Thakar; Sanjay B Maggirwar
Journal:  J Leukoc Biol       Date:  2017-06-29       Impact factor: 4.962

7.  Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets.

Authors:  C D Garlichs; S Eskafi; D Raaz; A Schmidt; J Ludwig; M Herrmann; L Klinghammer; W G Daniel; A Schmeisser
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

8.  Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients.

Authors:  S Danese; J A Katz; S Saibeni; A Papa; A Gasbarrini; M Vecchi; C Fiocchi
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

Review 9.  Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists.

Authors:  Ramya Kapadia; Jae-Hyuk Yi; Raghu Vemuganti
Journal:  Front Biosci       Date:  2008-01-01

10.  Levels of soluble CD40 ligand and P-Selectin in nonalcoholic fatty liver disease.

Authors:  Cemal Nuri Ercin; Teoman Dogru; Serkan Tapan; Yildirim Karslioglu; Cem Haymana; Selim Kilic; Alper Sonmez; Zeki Yesilova; Ahmet Uygun; Mustafa Gulsen; Sait Bagci; M Kemal Erbil
Journal:  Dig Dis Sci       Date:  2009-05-14       Impact factor: 3.199
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.